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Contrast-enhanced Doppler Ultrasound for
Guiding Percutaneous Microwave Ablation
of Hepatocellular Carcinoma:
A Report of 32 Cases
Xue-Dong Deng,1,2 Yan-Zheng Shen,1 Min Huang,1 Yu Yan1 and Qin Sun1
Objective: To evaluate the usefulness of contrast-enhanced Doppler ultrasound
for percutaneous microwave ablation therapy (PMAT) of hepatocellular carcinoma
(HCC).
Methods: A total of 51 hepatic tumors in 32 patients with HCC were treated
using a microwave system with a frequency of 2,450 MHz. Before and after PMAT,
color Doppler imaging with a bolus injection of Levovist® (Schering AG, Berlin,
Germany), at a dose 5 mL at 400 mg/mL, was performed with an A 128 XP10/
ART unit (Acuson, Mountain View, CA), with a probe frequency of 3.5 MHz.
Results: Immediately after PMAT, gray-scale ultrasound imaging of the treated
tumor appeared as a hyperechoic area with an acoustic shadow around the electrode.
Non-contrast-enhanced color flow signals were detected in all 51 nodules before
treatment, while color flow signals disappeared in 49 (96.1%) nodules and were
still present in two nodules after the treatment. Contrast-enhanced sonography with
Levovist® demonstrated only 36 nodules without flow signals and 15 nodules still
having flow signals, 30 days after PMAT. Based on contrast-enhanced ultrasound
findings, the residual tumor regions with blood flow signals were treated again within
1 month. Twenty-one of 32 patients had follow-up within 18 months (65.6%).
Conclusion: Contrast-enhanced Doppler ultrasound is useful for evaluating
ultrasound-guided PMAT for HCC.
(J Med Ultrasound 2004;12:75–81)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the second
leading killer from the class of malignant tumors in
China [1]. Surgical resection is still the treatment
method of choice, but only less than 20% of cases
are eligible for resection, due to advanced tumor
stage and underlying liver cirrhosis [2,3]. HCC also
has a high tendency to recur, even after successful
tumor removal, which typically requires repeated
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treatment. This additional intervention may result in
severely impaired liver function. To maximally
preserve liver function for surgically non-resectable
patients, effective treatment should be as minimally
invasive as possible.
Ultrasound-guided percutaneous microwave
ablation therapy (PMAT) is one of the relatively new
thermal coagulation techniques for the treatment of
HCC. In 1994, Seki et al first reported PMAT as an
effective method for the treatment of small (< 2 cm)
HCCs [4]. Since then, satisfactory therapeutic results
from PMAT for the treatment of small HCCs have
been reported by many investigators [5–11]. A
potential benefit of this technique is that it offers
treatment for patients who are not surgical candidates,
and it may reduce morbidity associated with surgery.
However, the efficacy of PMAT for hepatic tumors
larger than 2 cm has not been well investigated. The
purpose of this study was to use contrast-enhanced
ultrasound imaging (CEUSI) to evaluate the
usefulness of PMAT for hepatic tumors larger than
2 cm, commonly seen in a clinical setting.
PATIENTS AND METHODS
Thirty-two patients with pathologically confirmed
HCC were treated with PMAT, from May 1999 to
July 2001. There were 24 males and eight females
with a mean age of 52.4 years (range, 32–70 years).
All patients were clinically classified as non-surgical
candidates for tumor removal, based on one or more
of the following factors: poor liver function, elderly
patients with chronic kidney or heart disease, multiple
segmental lesions, and recurrent HCC. Of the 32
patients, 22 had one lesion, three had two lesions,
five had three lesions, and two had more than three
lesions. The maximum dimension of the lesions ranged
from 3 to 15 cm (8.27 cm ( 0.81 cm). Histologic
diagnosis was established by ultrasound-guided
biopsies with an 18-gauge cutting biopsy needle
(Type Quickcut–2, Hakko, Japan). All PMAT
procedures were performed at an interventional
ultrasound room. Written informed consent was
obtained from each patient at enrollment, and
ultrasound follow-up was carried out continuously
until December 2002.
Patients who had uncontrollable ascites or
coagulopathy (prothrombin activity < 40%, pro-
thrombin time > 25 seconds, platelet count < 50 =
109/L) were excluded from this study.
Microwave ablation
An HSE–8M microwave coagulation system
(Microtaze, AZWELL Inc, Osaka, Japan) with a
microwave frequency of 2,450 MHz and a power
output ranging from 10 to 80 W was used. The
system was equipped with a 14G needle electrode
(1.4 mm in diameter) with a 3-cm uninsulated tip.
The surface of the electrode was coated with a
Teflon coating, to prevent tissue charring. Based
on previous experience and tumor size [5], the
microwave power setting was 60 W and the duration
of each ablation ranged from 60 to 300 seconds
(tumors < 4 cm = 60 seconds; tumors 4–6 cm =
120 seconds; tumors 6–10 cm = 200 seconds; and
tumors > 10 cm = 300 seconds).
Ultrasound
A 128 XP10/ART unit (Acuson, Mountain View,
CA) with a 3.5 MHz phased array transducer was
used in this study. A contrast agent, Levovist®
(Schering AG, Berlin, Germany), was administered
intravenously at a dose of 5 mL at 400 mg/mL
before and after PMAT. Contrast-enhanced color
Doppler imaging (CECDI) was used to evaluate
tumor vascularity.
Ablation procedure
With intravenous anesthetics administered by an
anesthesiologist, an electrode was inserted into the
center of the tumor under ultrasound guidance. To
achieve complete destruction of tumors larger than
4 cm, we first positioned the tip of the electrode
in the distal margin of the tumor. Due to the fact
that 60-W output and a 300-second duration can
create a coagulation area of 4 = 2.7 = 2.6 cm, four
or five insertions were used for the deep portion of
the tumor. After the deep portion of the tumor was
coagulated, the electrode was relocated to superficial
areas for overlapping ablation, until the entire tumor
was destroyed within four or five insertions.  For the
large tumor (> 4 cm), a complete treatment was
performed over two sessions and within 1 week.
When color Doppler imaging and CEUSI identified
a feeding vessel within the tumor, the electrode was
first placed within this vessel and destroyed it, before
ablating the other areas.
ASSESSMENT OF EFFICACY
One month after PMAT, all patients were examined
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via dynamic computed tomography imaging (CT).
Two radiologists without knowledge of the treatment
results reviewed the images separately. Tumor areas
with uniformly low attenuation and no enhancement
were considered to be necrotic tumor tissue.
CEUSI was performed for all patients at 15, 30
and 75 days after PMAT, by two independent
radiologists who were unaware of the treatment
sessions. Tumor size was measured in three
dimensions before and after PMAT. The thermal
lesions of a treated area appeared as hypoechoic
areas. If blood vessels within the ablated area were
detected by CECDI, local recurrence or incomplete
necrosis of the tumor was considered present. Blood
samples were tested to determine the serum _-
fetoprotein level and liver function before PMAT
and 2–4 weeks after percutaneous microwave
coagulation therapy.
RESULTS
Thirty-two patients had follow-up for 6–43 months
after completion of PMAT. Of the 32 patients, 21
had follow-up within 18 months (65.6%) and were
still alive. Twenty-seven patients survived past the
end of 2002, and consulted periodically as outpatients.
Five patients had died by the end of this study,
where one fatality was from advanced HCC, three
were from systemic metastasis, and one was from
bleeding in the upper gastrointestinal tract.
Immediately after microwave ablation, gray-scale
ultrasound imaging of the treated tumor appeared
as a hyperechoic area, with an acoustic shadow
around the electrode. This hyperechoic area diffused
over time and completely disappeared within 6–8
hours. After PMAT, the changes of sonographic
appearance depended on the initial echogenic pattern
of the tumor. In most cases (48 of 51 nodules), the
hypoechoic tumors increased echogenicity, and
hyperechoic lesions showed heterogeneous hyper-
echogenicity after therapy. Two weeks after treatment,
all of the 51 nodules began to shrink to some degree
(7.5–11.9% decrease in diameter).
Non-contrast-enhanced color flow signals were
detected in all 51 nodules before the treatment,
while color flow signals disappeared in 49 (96.1%)
nodules after PMAT. Among these, 12 of 49 were
confirmed pathologically at operation (Figure 1) and
were still present in two nodules 30 days post-
treatment. Contrast-enhanced color flow signals were
detected in all 51 nodules before the treatment.
However, contrast-enhanced sonography with
Levovist® demonstrated only 36 nodules without
flow signals and 15 nodules still having flow signals
30 days after PMAT (Table and Figure 2). Based
on the contrast-enhanced ultrasound findings,
combined with contrast-enhanced CT, the residual
tumor regions with blood flow signals received
additional ablation within 1 month (residual tumors
were confirmed pathologically by ultrasound-guided
biopsy in 5 of 15 nodules).
CEUSI was performed 15 days after ablation
revealed 31 nodules without flow signals, and 20
nodules still showed flow signals. At 75 days after
ablation, CEUSI revealed 17 nodules with flow
signals, and 34 nodules without flow signals.
Forty-two of 51 nodules (82.3%) showed
enhancement on contrast-enhanced CT before
treatment. The other nine nodules failed to show
enhancement. Two possible reasons for this failure
include tumors with portal vein supplying or tumors
with sclerosis may not show enhancement. One month
after the treatment, contrast-enhanced CT revealed
that blood vessels (arteries) within the tumors were
not evident in 38 of 51 lesions (74.5%).
Serum levels of _-fetoprotein were tested in all
32 patients before treatment. Of these patients, 12
had normal serum _-fetoprotein levels (< 20 mg/L),
and 20 patients (59.40%) had elevated serum
_-fetoprotein levels. Within 2–4 weeks after
treatment, the _-fetoprotein levels had decreased in
16 of 20 patients who had elevated _-fetoprotein
values before ablation.
DISCUSSION
Percutaneous ethanol injection therapy is widely used
for the treatment of small liver cancers. Because of
the uneven distribution of ethanol in tumor tissue,
tumor destruction can be incomplete, especially
tumors larger than 2 cm in size [12,13].  Radio-
frequency ablation and PMAT are two thermal
ablation therapies developed in recent years [14,15].
Compared to percutaneous ethanol injection therapy,
these two modalities have the advantage of creating
a relatively even coagulation area, thereby providing
more reliable ablation for HCC [10]. At present,
PMAT is mainly used for tumors smaller than 4 cm.
For larger tumors, the local effectiveness of this
method is less promising.
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Fig. 1. A 45-year-old man with liver metastasis. (A) Ultrasound showed a mass of 55 mm = 50 mm before percutaneous
microwave ablation therapy (PMAT). (B) Metastasis was confirmed by pathology. (C) Specimen after PMAT. (D)
After ablation, necrosis was confirmed by pathology.
Table. Evaluation of tumor arteries 30 days after
percutaneous microwave ablation therapy, using
Levovist® contrast ultrasound and color Doppler
flow imaging (CDFI)
Levovist®
CDFI + – Total
  + 2 0 2
  – 13 36 49
Total 15 36 51
For percutaneous thermal ablation, coagulation of
the whole tumor and its margin is essential for
achieving complete tumor necrosis. Therefore, finding
methods of expanding the coagulated area is a key
issue worth studying. A number of investigators
have implemented novel methods of creating larger
volumes of coagulated necrotic tissue. Goldberg et
al showed that increased tissue destruction could be
achieved using multiple electrodes [15]. McGahan et
al, for their part, showed that bipolar radiofrequency
can be effective in increasing the volume of tissue
coagulation, compared with the monopolar techniques
[16].
Seki et al reported long-term results of PMAT
for solitary HCCs 2 cm or smaller in diameter; the
5-year survival rate was reported as more than 70%
[10]. In their study, PMAT was performed in 50
patients with 107 nodules, which included 61 nodules
larger than 2 cm in diameter. The 1, 2, and 3-year
survival rates were 96%, 83%, and 73%, respectively.
In contrast, the 3-year survival rate in untreated
patients with HCCs smaller than 3–5 cm is only
12.8–21.0% [17,18]. These results suggest that PMAT
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Another important factor affecting therapeutic
efficacy is the management of tissue blood perfusion.
In a study by Rossi et al, the volume of coagulated
necrosis was limited because of the proximity of
large vessels that acted as a heat sink during
radiofrequency thermal therapy [17]. After occlusion
of arterial blood flow to the tumor, the researchers
found that the area of coagulated necrosis was
significantly enlarged. From our study, we feel that
ablation of the feeding vessels was a useful technique
for coagulating the tumor. With the help of CEUSI,
we could easily find the feeding vessels for the
tumor.
Many modalities, such as CT, magnetic resonance
imaging, ultrasound, and fine-needle aspiration
biopsy, have been used to assess the efficacy of
PMAT. Each has its advantages and disadvantages.
CT is generally accepted as the standard and most
reliable method of evaluating the extent of tumor
necrosis induced by treatment, because, after the
administration of a contrasting agent, the presence
of vascular enhancement usually signifies the
persistence of viable tumors. Furthermore, non-
enhancement normally represents the absence of
visable tumor tissue. However, hepatic artery-related
enhancement can sometimes be observed in normal
liver tissue adjacent to the necrotic region on follow-
up CT, and such a reading may be misinterpreted
as incomplete necrosis [20,21].
Characterization of liver cancer by ultrasound has
traditionally been performed solely on the basis of
gray-scale morphologic features. The addition of
color, power, and spectral Doppler provides additional
vascular information. Unfortunately, the use of
conventional Doppler to provide this vascular
information is often limited in the evaluation of liver
Fig. 2. (A) In a 42-year-old man with a solitary mass on the left lobe, contrast-enhanced ultrasound imaging shows
multiple vessels within the tumor before microwave ablation. (B) Ultrasound-guided biopsy with pathology confirmed
hepatocellular carcinoma. (C) 15 days after ablation, ultrasound contrast imaging shows residual viable tumor with
multiple vessels. (D) After the second ablation, contrast-enhanced imaging shows no tumor vessels detected.
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masses, which may be located deep in the abdomen,
small in size, and prone to motion artifacts from
either respiratory or cardiac movements. In order
to overcome these limitations, Doppler signals with
the use of ultrasound contrast agents have greatly
improved. The contrast agent used in this study was
useful for assessing the completeness of ablation, in
which hypoechoic change without vessel
enhancement represented necrotic tissue. Based on
our experience, contrast-enhanced color Doppler flow
imaging (CDFI) ultrasound is more sensitive than
CDFI for evaluating PMAT treatment (p < 0.01).
Our present and previous studies suggest that
ultrasound contrast should be performed 1 month
after ablation, and considered as a gold standard for
evaluating and monitoring microwave ablation [6,
7]. According to our study, around 15 days after
ablation, a hyperemic response surrounding the
ablation area may be confused with peripheral tumor
re-growth at CEUSI. Also, we found that 75 days
after ablation was too late to evaluate local recurrence,
therefore missing the best opportunity for treatment.
Thirty days after ablation was our time of choice
for assessing the response to ablation.
In conclusion, the use of CEUSI has several
advantages over CT and conventional color Doppler.
First, there are none of the problems related to wor-
king with X-ray; secondly, CEUSI has capabilities
for easily detecting feeding vessels within tumors,
important for ablation; and thirdly, the contrast agent
is useful for assessing completeness of ablation and
evaluating prognosis. Finally, our results showed a
significant difference between contrast-enhanced
ultrasound and conventional color Doppler for
evaluating the completeness of ablation.
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